Cohance Lifesciences Limited (NSE:COHANCE)

India flag India · Delayed Price · Currency is INR
279.90
-11.95 (-4.09%)
At close: Mar 6, 2026
-76.18%
Market Cap 107.08B
Revenue (ttm) 10.79B
Net Income (ttm) 606.40M
Shares Out 382.57M
EPS (ttm) 2.35
PE Ratio 119.13
Forward PE 37.12
Dividend n/a
Ex-Dividend Date n/a
Volume 2,396,684
Average Volume 1,749,581
Open 290.35
Previous Close 291.85
Day's Range 276.00 - 295.00
52-Week Range 276.70 - 1,250.00
Beta 0.15
RSI 22.15
Earnings Date Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores... [Read more]

Sector Healthcare
Founded 1989
Employees 1,212
Stock Exchange National Stock Exchange of India
Ticker Symbol COHANCE
Full Company Profile

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.

Financial Statements

News

There is no news available yet.